Quote:
Originally Posted by opendoor
And yet, Pfizer's stock price is exactly where it was 5 years ago. Meanwhile Merck & Co (who didn't have a successful COVID vaccine and whose treatment had mediocre results) has seen their stock price double in that same period.
COVID-related things are certainly driving revenue, but I'm not sure they're leading to any kind of long-term profitability.
|
Pfizers revenue doubled for two years so I'm sure they would have loved to continue handing out vaccines but everyone realized the vaccine wasn't very effective and Covid wasn't that serious to the majority of people. They capitalized while they could.